All news

Synchron implants Stentrode in 15 people and prepares to read several brain areas at once

Prepared by Sintelligent with the help of SI. Published in SI: . Updated: .

The Stentrode is delivered through blood vessels without opening the skull, and Synchron has brought the number of implantations to 15, planning to read several brain areas at once.

Synchron founder and CEO Thomas Oxley told Fortune on November 21 that the company has implanted the Stentrode in 15 people, adding five over the year. Over the same period the number of participants with a Neuralink implant grew from seven to about 26, according to Fortune. According to him, Synchron is preparing a more powerful device that reads several brain areas at once without opening the skull (whole-brain sensing). It is intended, among others, for patients with age-related cognitive decline, and Oxley described the timeline for its release as "soon". A Merge Labs representative (co-founder Sam Altman; OpenAI invested in early 2026) told Fortune the product would be unveiled in "a couple of months". Oxley also called China, where the first commercial neurointerface was approved in March 2026, a serious source of concern.

Sources 1

History

Synchron: Stentrode implants and neural interface trials

2 events
    1. Synchron implants Stentrode in 15 people and prepares to read several brain areas at onceOpen now
    1. Synchron pauses trials of its second-generation neural interface